Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Evgen Pharma ( (GB:TCF) ) has provided an announcement.
TheraCryf plc has announced a significant milestone in its Ox-1 addiction program, achieving a 0.5kg scale-up of the compound ahead of schedule, with plans to progress to a 10kg scale-up. This advancement is crucial for upcoming in vivo studies and 28-day toxicology studies, which will inform dosing for future clinical trials. The company is also preparing for a Phase 1 healthy volunteer study by manufacturing human-grade drug products under Good Manufacturing Practice (GMP) standards. These developments are expected to bolster TheraCryf’s position in the brain disorder drug development industry and support its goal of submitting a clinical trial application.
Spark’s Take on GB:TCF Stock
According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.
Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.
To see Spark’s full report on GB:TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a clinical stage drug development company focusing on brain disorders, with a broad clinical and preclinical pipeline targeting conditions such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data sets to achieve preclinical and/or clinical proof of concept and partner its clinical programs with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is headquartered in Alderley Park, Cheshire, trading on AIM in London under the ticker symbol TCF.
Average Trading Volume: 4,304,865
Technical Sentiment Signal: Sell
Current Market Cap: £4.51M
For an in-depth examination of TCF stock, go to TipRanks’ Overview page.